Acute leukaemia following renal transplantation

Sklarin, N.T., Dutcher, J.P. and Wiernik, P.H. (1991) Lym-phomas following cardiac transplantation.Am.J. Hematol. 37, 105–11.

Penn, I. (1989) Why do immunosuppressed patients develop cancer?Crit. Rev. Oncol. 1, 27–52.

Cuzick, J., Erskine, S. and Edelman, D. (1987) A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphelan and cyclo- phosphamide treatment for myelomatosis.Br. J. Cancer 55, 523–9.

Greene, M.H., Harris, E.L., Gershenson, D.M., Malkasian Jr, G.D., Melton III, L.J., Dembo, A.J., Bennett, J.M., Moloney, W.C. and Boice, J.D. (1986) Melphelan may be a more potent leukemogen than cyclophosphamide.Ann. Int. Med. 105, 360–7.

Fisher, B., Rockette, H., Fisher, E.R., Wickerham, D.L., Redmond, C. and Brown, A. (1985) Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: The NSABP experience.J. Clin. Oncol. 3, 1640–58.

Greene, M.H., Young, R.C., Merrill, J.M. and DeVita, V.T. (1983) Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin’s lymphoma.Cancer Res. 43, 1891–8.

Kantarjian, H.M., Keating, M.J., Walters, R.S., Beran, M., McGlaughlin, P., McCredie, K.B. and Freireich, E.J. (1986) The association of specific ‘favorable’ cytogenetic abnormalities with secondary leukemia.Cancer 58, 924–7.

Fenaux, P., Lucidarme, D., Lai, J.L. and Bauters, F. (1989) Favorable cytogenetic abnormalities in secondary leukemia.Cancer 63, 2505–8.

Githens, J.H., Rosenkrantz, J.G. and Tunnock, S.M. (1965) Teratogenic effects of azathioprine (Imuran).J. Pediatr. 66, 959–61.

IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans (1981)Some Antineoplastic and Immunosuppressive Agents, Vol. 26. Lyon: World Health Organization International Agency For Research on Cancer.

Jensen, M.K. (1967) Chromosome studies in patients treated with azathioprine and amethopterin.Acta Med. Scand. 182, 445–55.

Fukuda, M., Aikawa, I., Ohmori, Y., Yoshimura, N., Nakai, L, Matri, S. and Oka, T. (1987) Chromosome aberrations in kidney transplant recipients.Transpl. Proc. 19, 2245–7.

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans (1987)Genetic and Related Effects, Suppl 6. Genetic and Related Effects. Lyon: World Health Organisation International Agency for Research on Cancer.

Rosenkranz, H.S. and Klopmen, G. (1991) A re-examination of the genotoxicity and carcinogenicity of azathioprine.Mutat. Res. 251, 157–61.

Voogd, C.E. (1989) Azathioprine, a genotoxic agent to be considered non-genotoxic in man.Mutat. Res. 221, 133–52.

Escalante, A., Kaufman, R.L. and Beardmore, T.D. (1989) Acute myelocytic leukemia after the use of cyclophosphamide in the treatment of polyarteritis nodosa.J. Rheumatol. 16, 1147–9.

Burke, G.W., Cirocco, R., Markou, M., Temple, S.D., Allouch, M., Roth, D., Nery, J. and Miller, J. (1995) Early development of acute myelogenous leukemia following kidney transplantation: Possible role of multiple serum cytokines.Leuk. Lymph. 19, 173–80.

Kantarjian, H.M., Keating, M.J., Walters, R.S., Smith, T.L., Cork, A., McCredie, K.B. and Freireich, EJ. (1986) Therapy-related leukemia and myelodysplastic syndrome: Clinical, cytogenetic and prognostic features.J. Clin. Oncol 4, 1748–57.

Grunwald, H.W. and Rosner, F. (1979) Acute leukemia and immunosuppressive drug use: A review of patients undergoing immunosuppressive therapy for non-neoplastic diseases.Arch. Intern. Med. 139, 461–6.

Silvergleid, AJ. and Schrier, S.L. (1974) Acute myelogenous leukemia in two patients treated with azathioprine for nonmalignant disease.Am. J. Med. 57, 885–8.

Sheil, A.G., Disney, A.P., Mathew, T.H. and Amiss, N. (1993)De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation.Transpl. Proc. 25, 1383–4.

Penn, I. (1981) Depressed immunity and the development of cancer.Clin. Exp. Immunol. 46, 459–74.